Boundless Bio (BOLD) said late Friday it optimized its portfolio and streamlined operations, including a one-third reduction of its workforce to drive long-term value creation.
The company discontinued the monotherapy and combination arms of BBI-355 candidate in Potentiate clinical trial due to toxicity concerns and a narrow therapeutic index, according to the company.
Boundless will attempt clinical development by combining BBI-335 and ribonucleotide reductase inhibitor, BBI-825, for "synergistic" anti-tumor activity as a replication stress combination therapy, the company said, adding it would present scientific details backing this decision on May 27.
The company declared the BBI-940 development candidate for the novel Kinesin program, according to a statement.
The company noted that workforce reduction, optimized operations, and portfolio changes are expected to extend its cash runway into H1 2028.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.